These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36217441)

  • 1. The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy.
    Wang T; Lin F; Huang Y; Qian G; Yu W; Hu H; Ji T; Tang L; Yao Y
    Cancer Manag Res; 2022; 14():2945-2952. PubMed ID: 36217441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
    Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
    Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
    Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
    Front Oncol; 2022; 12():939343. PubMed ID: 35965587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
    Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
    Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
    Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
    Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
    Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
    Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns.
    Cai M; Zhu J; Zhou G
    Comput Math Methods Med; 2022; 2022():3287961. PubMed ID: 35991143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
    He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
    Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer.
    Huang JY; Xie XF; Chen XL; Zhang QY; Chen LP; Bai X; Lan XF; Song L; Guo JF; Du CW
    Front Oncol; 2023; 13():1122294. PubMed ID: 37124484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients.
    Qian Y; Lou K; Zhou H; Zhang L; Yuan Y
    Front Oncol; 2022; 12():1042451. PubMed ID: 36568219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
    Liu Y; Ge Q; Xu S; Li K; Liu Y
    Front Oncol; 2022; 12():942678. PubMed ID: 36059654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
    Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
    Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
    Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
    Front Oncol; 2022; 12():885350. PubMed ID: 35860585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
    Ma J; Song Y; Shou J; Bai Y; Li H; Xie X; Luo H; Ren X; Liu J; Ye D; Bai X; Fu C; Qin S; Wang J; Zhou AP
    Front Oncol; 2020; 10():664. PubMed ID: 32457838
    [No Abstract]   [Full Text] [Related]  

  • 17. Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy.
    Li H; Li Y; Song L; Ai Q; Zhang S
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e314-e319. PubMed ID: 36658675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
    Cai J; Zhou S; Luo Y; Liu A
    Medicine (Baltimore); 2021 Dec; 100(51):e28126. PubMed ID: 34941058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study.
    Liu J; Deng YT; Jiang Y
    Invest New Drugs; 2021 Apr; 39(2):330-336. PubMed ID: 32974853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
    Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
    Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.